Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Taking the patient and the patient's perspective into account to improve outcomes of care of patients with musculoskeletal diseases.

Oude Voshaar MAH, van de Laar MAFJ.

Best Pract Res Clin Rheumatol. 2019 Jun;33(3):101436. doi: 10.1016/j.berh.2019.101436. Epub 2019 Sep 6. Review.

PMID:
31703794
2.

[The next step in the treatment of immune diseases: jakinibs, inhibitors of the intracellular Janus kinase].

van de Laar MAFJ, Hoentjen F, Thio HB.

Ned Tijdschr Geneeskd. 2019 Aug 19;163. pii: D3569. Dutch.

PMID:
31433146
3.

Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaeybroeck B, Klaasen R, van Onna M, Bernelot Moens HJ, Visser H, Schilder AM, Kok MR, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

BMC Rheumatol. 2019 Jun 13;3:3. doi: 10.1186/s41927-019-0071-x. eCollection 2019. Erratum in: BMC Rheumatol. 2019 Aug 20;3:35.

4.

Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy.

Ten Klooster PM, Oude Voshaar MAH, Fakhouri W, de la Torre I, Nicolay C, van de Laar MAFJ.

Clin Rheumatol. 2019 Oct;38(10):2727-2736. doi: 10.1007/s10067-019-04600-7. Epub 2019 Jun 3.

PMID:
31161488
5.

Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.

Janssen CA, Oude Voshaar MAH, Ten Klooster PM, Vonkeman HE, van de Laar MAFJ.

Clin Rheumatol. 2019 Aug;38(8):2233-2239. doi: 10.1007/s10067-019-04566-6. Epub 2019 Apr 27.

PMID:
31030363
6.

Psychometric properties and cross-language equivalence of the revised Bristol Rheumatoid Arthritis Fatigue and the Rheumatoid Arthritis Impact of Disease scales in rheumatoid arthritis.

Oude Voshaar MAH, Bode C, Hewlett S, Kirwan J, Gossec L, van de Laar MAFJ.

Qual Life Res. 2019 Sep;28(9):2543-2552. doi: 10.1007/s11136-019-02188-8. Epub 2019 Apr 26.

7.

A systematic literature review of patient-reported outcome measures used in gout: an evaluation of their content and measurement properties.

Janssen CA, Oude Voshaar MAH, Ten Klooster PM, Jansen TLTA, Vonkeman HE, van de Laar MAFJ.

Health Qual Life Outcomes. 2019 Apr 11;17(1):63. doi: 10.1186/s12955-019-1125-x.

8.

Development and validation of a patient-reported gout attack intensity score for use in gout clinical studies.

Janssen CA, Oude Voshaar MAH, Ten Klooster PM, Vonkeman HE, van de Laar MAFJ.

Rheumatology (Oxford). 2019 Nov 1;58(11):1928-1934. doi: 10.1093/rheumatology/kez064.

9.

Development and preliminary evaluation of a short self-report measure of generalized pain hypersensitivity.

van Bemmel PF, Voshaar MAO, Klooster PMT, Vonkeman HE, van de Laar MA.

J Pain Res. 2019 Jan 17;12:395-404. doi: 10.2147/JPR.S182287. eCollection 2019.

10.

Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial.

Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, Radovits B, van Durme C, Baan H, van de Laar MAFJ.

Rheumatology (Oxford). 2019 Jan 2. doi: 10.1093/rheumatology/key402. [Epub ahead of print]

PMID:
30602035
11.

A goal management intervention for patients with polyarthritis and elevated levels of depressive symptoms: a quasiexperimental study.

Arends RY, Bode C, Taal E, Van de Laar MAFJ.

Disabil Rehabil. 2018 Nov 19:1-10. doi: 10.1080/09638288.2018.1513086. [Epub ahead of print]

PMID:
30453793
12.

The International Consortium for Health Outcome Measurement (ICHOM)Set of Outcomes that Matter to People Living with Inflammatory Arthritis Consensus from an international Working Group.

Oude Voshaar MAH, Das Gupta Z, Bijlsma JWJ, Boonen A, Chau J, Courvoisier DS, Curtis JR, Ellis B, Ernestam S, Gossec L, Hale C, Hornjeff J, Leung KYY, Lidar M, Mease P, Michaud K, Mody GM, Ndosi M, Opava CH, Pinheiro GRC, Salt M, Soriano ER, Taylor WJ, Voshaar MJH, Weel AEAM, de Wit M, Wulffraat N, van de Laar MAFJ, Vonkeman HE.

Arthritis Care Res (Hoboken). 2018 Oct 24. doi: 10.1002/acr.23799. [Epub ahead of print]

13.

Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric.

Oude Voshaar MAH, Vonkeman HE, Courvoisier D, Finckh A, Gossec L, Leung YY, Michaud K, Pinheiro G, Soriano E, Wulfraat N, Zink A, van de Laar MAFJ.

Qual Life Res. 2019 Jan;28(1):187-197. doi: 10.1007/s11136-018-2007-0. Epub 2018 Oct 13.

14.

Rasch measurement in rheumatoid arthritis: deriving psychometrically optimal measures from the Rasch Everyday Activity Limitation item bank.

Oude Voshaar MAH, Ten Klooster P, Vonkeman HE, van de Laar MAFJ.

Rheumatology (Oxford). 2018 Oct 1;57(10):1761-1768. doi: 10.1093/rheumatology/key154.

PMID:
29939313
15.

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, Schilder AM, Visser H, Sasso EH, Chernoff D, Lems WF, van Schaardenburg DJ, Landewe R, Bernelot Moens HJ, Radstake TRDJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

PLoS One. 2018 May 23;13(5):e0192425. doi: 10.1371/journal.pone.0192425. eCollection 2018.

16.

An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.

Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, Vonkeman HE, Boonen A, Clarke P, McColl G, Ten Klooster PM, Zijlstra TR, Lems WF, Riyazi N, Griep EN, Hazes JMW, Landewé R, Bernelot Moens HJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2018 Oct;70(10):1557-1564. doi: 10.1002/art.40546. Epub 2018 Aug 23.

17.

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.

Janssen CA, Oude Voshaar MAH, Vonkeman HE, Krol M, van de Laar MAFJ.

Clin Rheumatol. 2018 Aug;37(8):2291-2296. doi: 10.1007/s10067-018-4127-x. Epub 2018 May 2.

18.

Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice.

Versteeg GA, Steunebrink LMM, Vonkeman HE, Ten Klooster PM, van der Bijl AE, van de Laar MAFJ.

Clin Rheumatol. 2018 May;37(5):1189-1197. doi: 10.1007/s10067-017-3962-5. Epub 2018 Feb 1.

19.

Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry.

Steunebrink LMM, Versteeg LGA, Vonkeman HE, Ten Klooster PM, Hoekstra M, van de Laar MAFJ.

BMC Rheumatol. 2018 Jan 17;2:1. doi: 10.1186/s41927-018-0009-8. eCollection 2018.

20.

Development of an item bank to measure factual disease and treatment related knowledge of rheumatoid arthritis patients in the treat to target era.

de Jonge MJ, Oude Voshaar MAH, Huis AMP, van de Laar MAFJ, Hulscher MEJL, van Riel PLCM.

Patient Educ Couns. 2018 Jan;101(1):67-73. doi: 10.1016/j.pec.2017.07.019. Epub 2017 Jul 21.

PMID:
28811047
21.

Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.

Janssen CA, Jansen TLTA, Oude Voshaar MAH, Vonkeman HE, van de Laar MAFJ.

Rheumatol Int. 2017 Sep;37(9):1435-1440. doi: 10.1007/s00296-017-3777-3. Epub 2017 Jul 26.

22.

Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.

Ghiti Moghadam M, Ten Klooster PM, Vonkeman HE, Kneepkens EL, Klaasen R, Stolk JN, Tchetverikov I, Vreugdenhil SA, van Woerkom JM, Goekoop-Ruiterman YPM, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):516-524. doi: 10.1002/acr.23315.

23.

Measuring everyday functional competence using the Rasch assessment of everyday activity limitations (REAL) item bank.

Oude Voshaar MAH, Ten Klooster PM, Vonkeman HE, van de Laar MAFJ.

Qual Life Res. 2017 Nov;26(11):2949-2959. doi: 10.1007/s11136-017-1627-0. Epub 2017 Jun 21.

24.

Determinants of Perceived Health Nonimprovement in Early Rheumatoid Arthritis Patients With Favorable Treatment Outcomes.

Steunebrink LMM, Oude Voshaar MAH, Taal E, Vonkeman HE, Zijlstra TR, van de Laar MAFJ.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):510-515. doi: 10.1002/acr.23305. Epub 2018 Mar 7.

25.

Measuring Disease Exacerbation and Flares in Rheumatoid Arthritis: Comparison of Commonly Used Disease Activity Indices and Individual Measures.

Voshaar MAHO, Moghadam MG, Vonkeman HE, Ten Klooster PM, van Schaardenburg D, Tekstra J, Visser H, van de Laar MAFJ, Jansen TL.

J Rheumatol. 2017 Aug;44(8):1118-1124. doi: 10.3899/jrheum.160915. Epub 2017 May 15.

PMID:
28507187
26.

Development of a web-based patient decision aid for initiating disease modifying anti-rheumatic drugs using user-centred design methods.

Nota I, Drossaert CHC, Melissant HC, Taal E, Vonkeman HE, Haagsma CJ, van de Laar MAFJ.

BMC Med Inform Decis Mak. 2017 Apr 26;17(1):51. doi: 10.1186/s12911-017-0433-5.

27.

The added value of synovial fluid centrifugation for monosodium urate and calcium pyrophosphate crystal detection.

Boumans D, Hettema ME, Vonkeman HE, Maatman RG, van de Laar MA.

Clin Rheumatol. 2017 Jul;36(7):1599-1605. doi: 10.1007/s10067-017-3633-6. Epub 2017 Apr 19.

PMID:
28424907
28.

Validation of automatic joint space width measurements in hand radiographs in rheumatoid arthritis.

Schenk O, Huo Y, Vincken KL, van de Laar MA, Kuper IH, Slump KC, Lafeber FP, Bernelot Moens HJ.

J Med Imaging (Bellingham). 2016 Oct;3(4):044502. Epub 2016 Nov 23.

29.

Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs.

Nota I, Drossaert CH, Taal E, Vonkeman HE, Haagsma CJ, van de Laar MA.

Arthritis Res Ther. 2016 Oct 28;18(1):252.

30.

A mixed-methods process evaluation of a goal management intervention for patients with polyarthritis.

Arends RY, Bode C, Taal E, Van de Laar MA.

Psychol Health. 2017 Jan;32(1):38-60. Epub 2016 Nov 7.

PMID:
27662241
31.

Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry.

Manders SH, Kievit W, Jansen TL, Stolk JN, Visser H, Schilder AM, Vonkeman HE, Adang E, van de Laar MA, van Riel PL.

J Rheumatol. 2016 Oct;43(10):1787-1794. Epub 2016 Aug 1.

PMID:
27481900
32.

Further Simplification of the Simple Erosion Narrowing Score With Item Response Theory Methodology.

Oude Voshaar MA, Schenk O, Ten Klooster PM, Vonkeman HE, Bernelot Moens HJ, Boers M, van de Laar MA.

Arthritis Care Res (Hoboken). 2016 Aug;68(8):1206-10. doi: 10.1002/acr.22793.

33.

Exploring Fatigue Trajectories in Early Symptomatic Knee and Hip Osteoarthritis: 6-year Results from the CHECK Study.

Botterman J, Bode C, Siemons L, van de Laar MA, Dekker J.

J Rheumatol. 2016 Jul;43(7):1413-20. doi: 10.3899/jrheum.150820. Epub 2016 May 15.

PMID:
27182065
34.

Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.

Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, Landewé R, Bernelot Moens HJ, van Riel PL, van de Laar MA, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2016 Aug;68(8):1810-7. doi: 10.1002/art.39626.

35.

Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.

Steunebrink LM, Vonkeman HE, ten Klooster PM, Hoekstra M, van Riel PL, van de Laar MA.

Clin Rheumatol. 2016 Mar;35(3):609-15. doi: 10.1007/s10067-016-3191-3. Epub 2016 Feb 6.

36.

The longitudinal relation between patterns of goal management and psychological health in people with arthritis: The need for adaptive flexibility.

Arends RY, Bode C, Taal E, van de Laar MA.

Br J Health Psychol. 2016 May;21(2):469-89. doi: 10.1111/bjhp.12182. Epub 2016 Jan 4.

PMID:
26726041
37.

The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis.

Bardin T, van de Laar MA.

Joint Bone Spine. 2015 Oct;82 Suppl 1:eS30-2. doi: 10.1016/S1297-319X(15)30005-1.

PMID:
26717800
38.

The Human and Economic Burden of Difficult-to-Treat Gouty Arthritis.

Bardin T, Voshaar MA, van de Laar MA.

Joint Bone Spine. 2015 Oct;82 Suppl 1:eS2-8. doi: 10.1016/S1297-319X(15)30002-6.

PMID:
26717799
39.

Foreword.

Bardin T, van de Laar MA.

Joint Bone Spine. 2015 Oct;82 Suppl 1:eS1. doi: 10.1016/S1297-319X(15)30001-4. No abstract available.

PMID:
26717797
40.

Construct Validation of a Multidimensional Computerized Adaptive Test for Fatigue in Rheumatoid Arthritis.

Nikolaus S, Bode C, Taal E, Vonkeman HE, Glas CA, van de Laar MA.

PLoS One. 2015 Dec 28;10(12):e0145008. doi: 10.1371/journal.pone.0145008. eCollection 2015.

41.

Patient-centred care in established rheumatoid arthritis.

Voshaar MJ, Nota I, van de Laar MA, van den Bemt BJ.

Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4-5):643-63. doi: 10.1016/j.berh.2015.09.007. Epub 2015 Oct 29. Review.

PMID:
26697772
42.

Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry.

Manders SH, van de Laar MA, Rongen-van Dartel SA, Bos R, Visser H, Brus HL, Jansen T, Vonkeman HE, van Riel PL, Kievit W.

RMD Open. 2015 Oct 8;1(1):e000147. doi: 10.1136/rmdopen-2015-000147. eCollection 2015.

43.
44.

Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis.

Koop SM, ten Klooster PM, Vonkeman HE, Steunebrink LM, van de Laar MA.

Arthritis Res Ther. 2015 Sep 3;17:237. doi: 10.1186/s13075-015-0761-8.

45.

Exploring preferences for domain-specific goal management in patients with polyarthritis: what to do when an important goal becomes threatened?

Arends RY, Bode C, Taal E, Van de Laar MA.

Rheumatol Int. 2015 Nov;35(11):1895-907. doi: 10.1007/s00296-015-3336-8. Epub 2015 Aug 12.

46.

Comparison of 2 Dosages of Intraarticular Triamcinolone for the Treatment of Knee Arthritis: Results of a 12-week Randomized Controlled Clinical Trial.

Popma JW, Snel FW, Haagsma CJ, Brummelhuis-Visser P, Oldenhof HG, van der Palen J, van de Laar MA.

J Rheumatol. 2015 Oct;42(10):1865-8. doi: 10.3899/jrheum.141630. Epub 2015 Aug 1.

PMID:
26233499
47.

Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures.

Oude Voshaar MA, Ten Klooster PM, Glas CA, Vonkeman HE, Taal E, Krishnan E, Bernelot Moens HJ, Boers M, Terwee CB, van Riel PL, van de Laar MA.

Rheumatology (Oxford). 2015 Dec;54(12):2221-9. doi: 10.1093/rheumatology/kev265. Epub 2015 Jul 29.

PMID:
26224306
48.

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.

Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL.

Arthritis Res Ther. 2015 May 22;17:134. doi: 10.1186/s13075-015-0630-5.

49.

Working mechanism of a multidimensional computerized adaptive test for fatigue in rheumatoid arthritis.

Nikolaus S, Bode C, Taal E, Vonkeman HE, Glas CA, van de Laar MA.

Health Qual Life Outcomes. 2015 Feb 21;13:23. doi: 10.1186/s12955-015-0215-7.

50.

Assessment of fatigue in rheumatoid arthritis: a psychometric comparison of single-item, multiitem, and multidimensional measures.

Oude Voshaar MA, Ten Klooster PM, Bode C, Vonkeman HE, Glas CA, Jansen T, van Albada-Kuipers I, van Riel PL, van de Laar MA.

J Rheumatol. 2015 Mar;42(3):413-20. doi: 10.3899/jrheum.140389. Epub 2015 Jan 15.

PMID:
25593225

Supplemental Content

Loading ...
Support Center